Sanofi gets rated buy today, agreeing with bullish ratings from the Wall Street and SA analysts' consensus. With a diverse ...

(Bloomberg) — Sanofi entered a fresh round of exclusive negotiations to sell control of its consumer health unit to Clayton Dubilier & Rice after France secured commitments on local employment and ...

Sanofi confirmed on Monday plans to sell a controlling stake in its over-the-counter unit to a US investment fund, after ...

Sanofi (SNY) and the US buyout firm are set to announce exclusivity as early as Monday, they said. State-owned investment firm Bpifrance is set to take a minority interest in the OTC unit as part ...

Sanofi announced that it has entered into exclusive negotiations with the US private equity firm Clayton, Dubilier & Rice (CD&R) to transfer around 50% controlling stake in Opella.

For Sanofi the issue is not strategic. Indeed, separating consumer health — think paracetamol, laxatives and other over-the-counter medicines — from its core biopharma activities is sensible.

(Reuters) - French drug maker Sanofi on Friday posted stronger earnings ... part of an industry trend to divest non-prescription drug units. The French drugmaker said at the time that adjusted ...

PARIS, Oct 21 (Reuters) - French drugmaker Sanofi (SASY.PA), opens new tab said on Monday it had entered exclusive talks to sell a 50% controlling stake in its consumer health business Opella to U ...

Sanofi SAN-0.92%decrease; red down pointing triangle is in discussions with the French government to address concerns officials raised about a potential sale of a controlling stake in the company ...

Sanofi SAN-1.01%decrease; red down pointing triangle moved ahead with a plan to sell a controlling stake in its consumer-healthcare unit Opella to Clayton Dubilier & Rice, entering exclusive talks ...

Sanofi’s shares traded 0.2% lower on Monday morning in Paris. The stock has risen about 2% over the past 12 months. Despite the commitments it faces in France, CD&R has been drawn to the Sanofi ...